Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
$3.49
+235.6%
$0.00
$0.91
$7.18
$112.21MN/A2.76 million shs175.17 million shs
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
$3.10
-2.2%
$3.16
$2.18
$7.90
$33.36M0.7221,058 shs5,364 shs
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$6.94
-5.2%
$5.92
$3.80
$26.70
$30.13M-0.8426,324 shs8,658 shs
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
$2.09
-13.6%
$1.87
$1.32
$7.66
$11.27M2.45212,898 shs156,712 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
0.00%+154.74%-14.25%+348,999,900.00%+348,999,900.00%
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
0.00%-5.49%+8.01%-50.28%-60.10%
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
0.00%-3.48%+4.38%+33.72%+13.94%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
0.00%+23.67%+29.81%-49.39%-97.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/AN/AN/AN/AN/AN/A
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
1.0727 of 5 stars
0.04.00.00.02.21.70.6
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
1.2556 of 5 stars
0.05.00.00.01.81.70.6
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
0.9624 of 5 stars
0.05.00.00.02.11.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
0.00
N/AN/AN/A
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
0.00
N/AN/AN/A
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
0.00
N/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
$10.05M6.41N/AN/AN/A
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
$515.82M0.06N/AN/A$10.56 per share0.29
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$383.96M0.08N/AN/A$56.67 per share0.12
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
$511.08K21.14N/AN/A$0.54 per share3.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/A0.00N/AN/AN/AN/AN/A
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
-$92.07M-$1.88N/AN/A-83.50%-60.68%-42.30%6/4/2025 (Estimated)
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
-$41.93MN/A0.00N/AN/AN/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
-$9.21M-$4.64N/AN/A-1,237.00%-138.00%-118.88%N/A

Latest MGRX, BNR, CCM, and BMGL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A-$1.29N/A-$1.29N/A$0.11 million
3/25/2025Q4 2024
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
-$1.3970-$1.08+$0.3170-$1.08N/A$17.27 million
3/20/2025Q4 2024
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A-$1.01N/A-$1.01N/A$0.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/AN/AN/A
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
N/AN/AN/AN/AN/A
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/AN/AN/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/A
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
N/A
3.04
2.78
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
1.15
0.47
0.46
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A
0.07
0.07

Institutional Ownership

CompanyInstitutional Ownership
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/A
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
30.03%
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
56.72%

Insider Ownership

CompanyInsider Ownership
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/A
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
30.30%
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
46.50%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
16.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
3618.46 millionN/AN/A
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
1,39010.76 million7.14 millionNot Optionable
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
9704.34 million2.32 millionNot Optionable
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
35.17 million1.51 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Basel Medical Group stock logo

Basel Medical Group NASDAQ:BMGL

$3.49 +2.45 (+235.58%)
As of 05/30/2025 04:00 PM Eastern

OUR MISSION Basel Medical transcends the role of a conventional healthcare provider. We strive for excellence in medical services and aim to serve as a beacon of hope for patients across Singapore and Southeast Asia. Our mission encompasses the four following commitments: Patient–Centered Care. We prioritize our patient’s wellbeing above all else. Innovation. We strive for excellence through innovation and expertise. Global Accessibility. We believe that quality healthcare should be universally available. Continuous Improvement. We constantly improve our services to meet evolving patient needs. With over 20 years of medical services experience, Basel Medical’s journey began with a simple commitment – to restore healthy and active lifestyles, one at a time. Today, that commitment has transformed into a vision for innovation, growth and far-reaching impact. We rely on an experienced group of medical practitioners to provide a wide spectrum of general and subspecialized orthopedic, trauma, sports medicine and neurosurgical services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery, minimally invasive orthopedic procedures and other complex neurosurgical procedures. We operate our two clinics at Gleneagles Medical Centre in Singapore and currently have five medical practitioners practicing with Basel Medical (together with its subsidiaries, the “Group”), comprising four orthopedic specialists and one neurosurgery specialist. The services provided by our clinics include, but are not limited to, consultation, medical diagnosis and medical or surgical treatments for orthopedic, trauma, sports medicine and neurological conditions and our clinics are equipped with the facilities needed to perform a variety of procedures on site and minor surgical services, while more complex surgical procedures are performed at operating theaters of other hospitals with such facilities. Our Group has a patient-oriented philosophy of providing personalized, quality and integrated medical care. We aim to be a one-stop integrated healthcare provider for all musculoskeletal-related medical care, including post-surgery rehabilitation services such as physiotherapy as well as other ancillary services such as pain management. Within the next 12 to 18 months, we intend to actively seek acquisition and collaboration partners in Singapore and Malaysia. Our acquisition and collaboration targets include general practitioner (GP) clinics and specialist clinics that complement our orthopedic services, particularly those focused on the musculoskeletal system, aging treatments, physiotherapy and occupational therapists. Our goal is to become an internationally known medical services provider in the Southeast Asian market, with a presence in at least four Southeast Asia countries (potentially covering Singapore, Malaysia, Indonesia and Thailand) within the next three years. As of the date of this prospectus, we have not identified such targets. Basel Medical was incorporated in the BVI on August 10, 2023 with registered number 2129740 as a BVI business company with liability limited by shares. Our BVI registered office is located at Kingston Chambers, PO Box 173, Road Town, Tortola, British Virgin Islands VG1110. Our principal executive offices are located in Singapore at 6 Napier Road, Unit #02-10/11 Gleneagles Medical Centre, Singapore. Our agent for service of process in the United States is Puglisi & Associates at 850 Library Avenue, Suite 204, Newark, Delaware.

Burning Rock Biotech stock logo

Burning Rock Biotech NASDAQ:BNR

$3.08 -0.09 (-2.81%)
As of 05/30/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Concord Medical Services stock logo

Concord Medical Services NYSE:CCM

$6.94 -0.38 (-5.19%)
Closing price 05/30/2025 02:37 PM Eastern
Extended Trading
$7.08 +0.14 (+2.02%)
As of 05/30/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.

Mangoceuticals stock logo

Mangoceuticals NASDAQ:MGRX

$2.09 -0.33 (-13.64%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$2.16 +0.08 (+3.59%)
As of 05/30/2025 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.